Gyre Therapeutics Inc
GYRE
Get informed when a big investor buys or sells
+ FollowMarket Cap$552.91M
Close$
$-1.76
129.6% downside
Current Fair Value
129.6% downsideOvervalued by 129.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $552.91 Million |
|---|---|
| Enterprise Value | $519.37 Million |
| Dividend Yield | $25.05 (-) |
| Earnings per Share | $0.06 |
| Beta | 4.78 |
| Outstanding Shares | 91,317,142 |
Return
| Return on Equity | -0.57% |
|---|---|
| Return on Assets | -0.35% |
| Return on Invested Capital | 19.50% |
Valuation & Multiples
| P/E Ratio | -81.87 |
|---|---|
| PEG | 32.03 |
| Price to Sales | 5.94 |
| Price to Book Ratio | 5.94 |
| Enterprise Value to Revenue | 4.44 |
| Enterprise Value to EBIT | 18.73 |
| Enterprise Value to Net Income | -904 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$31.61 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$26.49 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 3.73% |
|---|---|
| Total Invested | $39,398▼ 99.83% |
| Investors Holding | 6▼ 49.00% |
ESG Score
No data
About Gyre Therapeutics Inc
35 employees
CEO: Nassim Usman catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clin...